Introduction {#s1}
============

Valve-in-valve transcatheter aortic valve implantation (ViV TAVI) for degenerated aortic bioprostheses has been reported as an effective procedure in high risk patients. The transfemoral approach is the route of choice, but the transapical or transaortic approaches could be considered in case of severe peripheral vascular disease. Despite the good results obtained, a relevant risk of coronary ostia obstruction and myocardial ischemia has been observed during ViV TAVI procedures.

Case Report {#s2}
===========

An 80-year-old woman was admitted at emergency department for pulmonary edema. She was previously diagnosed with chronic type B aortic dissection arising from a Kommerell diverticulum and in 2008 she underwent aortic valve replacement (Mitroflow n° 23, Sorin, Saluggia, Italy) without correction of the aortic dissection (stable diameters, visceral perfusion from both lumens). Five years later, central severe aortic regurgitation appeared with moderate to severe mitral regurgitation, with reduced ejection fraction (EF) and pulmonary hypertension. In that occasion, chest X-rays was remarkable for the calcification of the vascular knobs ([Fig. 1](#F1){ref-type="fig"} A-D).

![(A-B): Chest X-ray in posteroanterior and laterolateral view. Calcifications of the vascular knobs (aortic arch on the left, right subclavian artery from the diverticulum on the right) and of the descending aorta are evident. (C): Severe aortic regurgitation from Mitroflow prosthesis dysfunction. (D): CT scan shows chronic type B aortic dissection and the calcified Kommerell diverticulum. (E): Intraprocedural angiography shows stenting of the left main after transapical Sapien XT released.](cr-09-133-g001){#F1}

The case was discussed by our internal Heart-Team. The estimated operative risk of the conventional redo aortic valve replacement was 32.5% (EuroSCORE II). A transcatheter strategy (TAVI) was evaluated but the transfemoral route and other transarterial ways were discarded due to aortic dissection. The transapical route was then chosen and a valve-in-valve TAVI performed (SAPIEN XT n° 23, Edwards Lifesciences, Irvine, CA).

We were conscious of risk of myocardial ischemia after a valve-in-Mitroflow procedure due to the peculiar design of this prosthesis (pericardial mounted outside the stent to optimize flow) and the unfavorable aortic root anatomy (narrow Valsalva sinuses and short distance between Mitroflow annulus and left coronary ostium). This structure may cause possible dislocation of Mitroflow pericardial leaflets overlapping coronary ostia during balloon expansion or TAVI valve deployment: so TAVI was done after protection of the left coronary artery with two intracoronary wires. Although without electrocardiographic alterations, considering the encumbrance of the Mitroflow leaflets, a protruding 5 × 20 mm bare metal stent was implanted in the left main ([Fig. 1E](#F1){ref-type="fig"}). Postoperative echocardiogram showed the correct positioning of the TAVI bioprosthesis with acceptable transprosthetic gradients and good EF (peak gradient 30 mm Hg, mean gradient 19 mm Hg, EF 53%). Postoperative course was uneventful. At 3 years follow-up, patient was in good clinical conditions. Echocardiogram showed the absence of aortic bioprosthesis failure (peak gradient 36 mm Hg, mean 21 mm Hg) and absence of left ventricular dysfunction (mean gradient 16 mm Hg, EF 55%) and mild to moderate mitral regurgitation. The bare metal stent previously implanted in the left main protruding in the aortic root was normally positioned ([Fig. 2](#F2){ref-type="fig"}).

![Late follow-up echocardiogram showing the correct positioning both of the TAVI prosthesis and of the stent implanted in the left main.](cr-09-133-g002){#F2}

Discussion {#s3}
==========

Several authors reported a worrisome early degeneration of Mitroflow bioprosthesis, mainly for small sizes, likely for the absence of an effective antimineralization treatment in first models such as Mitroflow LXA \[[@R01], [@R02]\]. ViV TAVI has been reported as an effective, fast, and less invasive treatment to overcome risks of redo operation mainly when surgical reoperation with a sutured or a sutureless prosthesis is contraindicated. However, ViV TAVI in small Mitroflow prostheses (19 - 21 mm) is associated with a risk of high postoperative gradients and risk of coronary ostia obstruction and acute myocardial ischemia \[[@R03]-[@R05]\]. In this case, of a degenerated Mitroflow 23 mm, ViV TAVI was considered feasible, and we didn't observe high postoperative gradients and patients-prosthesis mismatch. Coronary obstruction is a disastrous complication associated with high mortality. The global valve-in-valve registry reported an overall coronary obstruction rate of 3.5% and nearly 8% in degenerated Mitroflow bioprosthesis (all sizes included) \[[@R03]-[@R06]\].

High-risk features for intraprocedural myocardial ischemia include low-lying coronary ostia with a short distance between the annulus of the degenerated prosthesis and coronary ostia, short and narrow Valsalva sinuses, supra-annular surgical implantation of the first bioprosthesis, and the low-profile valve design with pericardial leaflets mounted outside an internal stent frame \[[@R04]-[@R06]\].

To prevent a periprocedural myocardial ischemia due to prosthesis leaflets stucked up against the coronary ostia, wiring of the left main was carried on for a faster potential revascularization in case myocardial ischemia during the procedure. In these conditions, a coronary angioplasty may be risky and possibly hampered by the struts of the new valve and the pericardial leaflets of the old Mitroflow prosthesis.

Indeed, preventive left main stenting was also performed in the same session before TAVI valve deployment, as an additional protection of the narrow access to the left main.

Conclusions {#s3a}
-----------

In cases of impracticable peripheral accesses such as for diffuse severe atherosclerotic disease or aortic dissection as in this case, transapical access for ViV TAVI with coronary protection could provide an effective way to the surgeon to replace a degenerated Mitroflow-type aortic valve in non-operable patients. Preventive stenting of the left main with a coronary stent protruding in the aortic root may confer a greater safety to the procedure.
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